At the news
? BULLISHIMPACT 6/10 8-K filed Jul 15, 2026 at 07:49 ET
JNJ reported Q2 2026 adjusted EPS of $2.90, a 1.6% beat vs. consensus of $2.85, on revenue of $25.31B (6.6% YoY growth, slightly above $25.06B consensus). The company raised its full-year 2026 adjusted EPS guidance by $0.13 to $11.68 at the midpoint (8.2% YoY growth) and raised its reported sales guidance to $101.1B at the midpoint (7.3% YoY growth). Strong performance was driven by Innovative Medicine (DARZALEX, CARVYKTI, TREMFYA, SPRAVATO) and MedTech (Cardiovascular, Surgery), partially offset by STELARA erosion from biosimilar competition.
- Q2 2026 reported sales of $25.31B, up 6.6% YoY, with operational growth of 5.6% and adjusted operational growth of 5.7%
- Adjusted EPS of $2.90 beat consensus of $2.85 by 1.6%
- Full-year 2026 adjusted EPS guidance raised by $0.13 to $11.68 midpoint (8.2% YoY growth)
- Full-year 2026 reported sales guidance raised to $101.1B midpoint (7.3% YoY growth)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access